Actuate therapeutics presents topline elraglusib phase 2 data at asco 2025 annual meeting: trial meets primary endpoint of median overall survival and doubles 1-year survival in first-line treatment of metastatic pancreatic cancer

Chicago and fort worth, texas, may 31, 2025 (globe newswire) -- actuate therapeutics, inc. (nasdaq: actu) (“actuate” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (gsk-3Β), today presented topline results from the phase 2 (actuate-1801 part 3b) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (gnp) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mpdac) at the american society of clinical oncology (asco) annual meeting.
ACTU Ratings Summary
ACTU Quant Ranking